ArticleIranian journal of medical sciences2025
Radiofrequency Catheter Ablation in Patients with Supraventricular Tachycardia: A Cohort Study on Efficacy, Safety, Anxiety, and Quality of Life Outcomes.
Article in Iranian journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Over the past two decades, radiofrequency catheter ablation (RFCA) has emerged as a leading treatment for cardiac arrhythmias due to its high efficacy, despite potential complications. This study evaluated success rates, complications, and the procedure's impact on quality of life (QoL) and anxiety in patients with supraventricular arrhythmia (SVT). Methods: This prospective cohort study involved patients diagnosed with SVT who were treated in Babol, Iran, between 2018 to 2019. The primary outcomes that were assessed included the immediate procedural success rate, success at 3 months post-ablation, associated complications, and their relationship with demographic and clinical factors. Additionally, changes in patients' QoL and anxiety levels before and after the procedure were analyzed. Procedures included recording His bundle electrograms using quadripolar catheters, performing programmed stimulations, autonomic blockade with atropine and propranolol, and delivering radiofrequency energy at target sites for at least 10 min. Complications and recurrence rates were monitored over a follow-up period of 3 months. Data were analyzed using SPSS software (version 23). Results: Immediate success was achieved in 98% of cases, with two failures due to complications. Recurrence occurred in 13% of patients within 3 months, significantly associated with higher BMI and diabetes (P=0.024; P=0.026), respectively. Post-procedure, anxiety levels decreased significantly (P<0.001), and all QoL dimensions improved substantially (P<0.001), highlighting the holistic benefits of the procedure. Conclusion: Overall, RFCA is an effective and well-tolerated treatment for SVT, demonstrating high success rates and significant improvements in patient outcomes, including reduced anxiety and enhanced QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.